Latest Medical Research News

Page 2 of 3
Recce Pharmaceuticals reported a 21% increase in net loss to $21.4 million for FY2025, driven by intensified R&D spending. The company secured key regulatory approvals for Phase 3 trials of its lead anti-infective gel and bolstered its financial position with significant capital raises and grants.
Ada Torres
Ada Torres
29 Aug 2025
4DMedical Limited reported a 56% jump in FY2025 operating revenue driven by SaaS growth, while narrowing its net loss to $30.1 million. The company also secured $13.9 million in capital and a $10 million funding facility to accelerate product commercialisation.
Ada Torres
Ada Torres
29 Aug 2025
Hearts and Minds Investments (HM1) reported a stellar 25.5% pre-tax portfolio return for FY25, outperforming global benchmarks and announcing a raised fully franked dividend of 9.0 cents per share with plans for continued increases.
Claire Turing
Claire Turing
29 Aug 2025
Hearts and Minds Investments Limited (HM1) reported a stellar FY25 with total comprehensive income soaring to $124.8 million, nearly doubling the prior year, alongside a dividend increase and sustained philanthropic commitments.
Claire Turing
Claire Turing
29 Aug 2025
Noxopharm Limited reported a 36.5% increase in its annual loss to $4.88 million as it progressed preparations for its SOF-SKN™ clinical trial and secured $2.6 million through convertible notes. The biotech continues to invest heavily in its inflammation and oncology drug pipeline while managing liquidity and strategic partnerships.
Ada Torres
Ada Torres
29 Aug 2025
Argenica Therapeutics reported a 34% revenue increase driven by R&D incentives but saw losses widen by 31% due to intensified clinical trial activity. The company is progressing its ARG-007 Phase 2 stroke trial and engaging with the FDA to lift a clinical hold.
Victor Sage
Victor Sage
28 Aug 2025
Nutritional Growth Solutions has settled to exit non-core US agreements, unlocking nearly $580,000 in financial relief and streamlining its strategic focus.
Ada Torres
Ada Torres
27 Aug 2025
Clever Culture Systems has validated and launched an AI-driven analysis module for smaller contact plates, significantly expanding its pharmaceutical market reach and recurring revenue potential.
Ada Torres
Ada Torres
27 Aug 2025
Recce Pharmaceuticals’ RECCE 327 Topical Gel shows statistically significant superiority over standard antibiotics in treating antibiotic-resistant burn wounds in preclinical models, advancing its U.S. Department of Defense collaboration.
Ada Torres
Ada Torres
12 Aug 2025
Nutritional Growth Solutions has completed a $760,000 share placement at a slight discount, aiming to boost inventory and support its retail growth strategy.
Victor Sage
Victor Sage
5 Aug 2025
Nutritional Growth Solutions Ltd has voluntarily suspended trading on the ASX pending a capital raising announcement, signaling a pivotal moment for the pediatric nutrition company.
Ada Torres
Ada Torres
5 Aug 2025
Recce Pharmaceuticals advances its clinical pipeline with expanded Phase 3 trials in Indonesia and Australia, backed by a $15.8 million capital raise and a $30 million debt facility.
Ada Torres
Ada Torres
31 July 2025